Immunophotonics Announces First Patient Treated in Swiss Clinical Trial
November 10, 2020
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the…
Potential COVID-19 Applications of Immunophotonics’ Leading Drug Candidate, IP-001, Being Researched at the University of Oklahoma
October 15, 2020
OU Daily at the University of Oklahoma recently published a story on research being conducted by Dr. Wei R. Chen…
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 5, 2020
October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a…
Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland
June 21, 2019
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled "Intratumoral Injection of IP-001 Following Thermal Ablation in…
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors
June 14, 2019
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and…